AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.
Close
Create a link to this page
Copy and paste this link tag into your Web page or blog:
<a href="http://www.accessmylibrary.com/coms2/summary_0286-23313039_ITM" title="Facts and information about FDA Antiviral Advisory Committee recommends approval for Bristol-Myers Squibb's investigational protease inhibitor Reyataz (atazanavir).">FDA Antiviral Advisory Committee recommends approval for Bristol-Myers Squibb's investigational protease inhibitor Reyataz (atazanavir).</a>
Close
Set up an RSS feed that alerts you when new articles from Asia Africa Intelligence Wire are available.
Frequently asked questions about RSS feeds
FDA Antiviral Advisory Committee recommends approval for Bristol-Myers Squibb's investigational protease inhibitor Reyataz (atazanavir).
(From Chemical Business NewsBase - Press Release)
Bristol-Myers Squibb Co is pleased that the US Food and Drug Administration's (FDA) Antiviral Drug Advisory Committee unanimously recommended to the FDA that it approve the investigational protease inhibitor atazanavir (Reyataz) for the treatment of HIV-1 infection. While the FDA is not bound by the committee's recommendation, in most cases, the FDA …
Related articles from newspapers, magazines, journals, and more
-
- Bristol-Myers Squibb statement on FDA Advisory Committee vote on Orencia...
-
News wire article from: Asia Africa Intelligence Wire
September 6, 2005
700+ words
-
- Bristol-Myers Squibb and Merck joint statement on FDA Advisory Committee vote...
-
News wire article from: Asia Africa Intelligence Wire
September 9, 2005
700+ words
-
- Press Release: Bristol-Myers Squibb receives FDA letter for Vanlev.
-
News wire article from: Asia Africa Intelligence Wire
October 11, 2002
700+ words
-
- Bristol Myers Squibb statement on FDA advisory committee vote on Baraclude...
-
News wire article from: Asia Africa Intelligence Wire
March 11, 2005
700+ words
-
- Bristol-Myers Squibb receives complete response letter from FDA for belatacept.
-
News wire article from: Chemical Business Newsbase
May 1, 2010
700+ words
